Lido Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $665K | Sell |
26,841
-1,664
| -6% | -$39.6K | ﹤0.01% | 1153 |
|
|
2025
Q4 | $562K | Hold |
28,505
| – | – | ﹤0.01% | 1257 |
|
|
2025
Q3 | $562K | Buy |
28,505
+4,083
| +17% | +$84K | ﹤0.01% | 1195 |
|
|
2025
Q2 | $530K | Sell |
24,422
-190
| -0.8% | -$4.49K | ﹤0.01% | 1088 |
|
|
2025
Q1 | $597K | Sell |
24,612
-46
| -0.2% | -$1.04K | ﹤0.01% | 960 |
|
|
2024
Q4 | $515K | Buy |
24,658
+2,650
| +12% | +$56.9K | ﹤0.01% | 1001 |
|
|
2024
Q3 | $438K | Buy |
22,008
+7,289
| +50% | +$135K | ﹤0.01% | 1002 |
|
|
2024
Q2 | $228K | Buy |
14,719
+75
| +0.5% | +$1.17K | ﹤0.01% | 1241 |
|
|
2024
Q1 | $233K | Sell |
14,644
-842
| -5% | -$12.7K | ﹤0.01% | 1205 |
|
|
2023
Q4 | $260K | Buy |
15,486
+4,275
| +38% | +$58.4K | ﹤0.01% | 1101 |
|
|
2023
Q3 | $131K | Sell |
11,211
-23,417
| -68% | -$313K | ﹤0.01% | 1125 |
|
|
2023
Q2 | $465K | Sell |
34,628
-11,368
| -25% | -$164K | ﹤0.01% | 769 |
|
|
2023
Q1 | $763K | Buy |
45,996
+33,597
| +271% | +$554K | 0.01% | 542 |
|
|
2022
Q4 | $231K | Sell |
12,399
-5,597
| -31% | -$86.2K | ﹤0.01% | 866 |
|
|
2022
Q3 | $230K | Sell |
17,996
-657
| -4% | -$7.79K | ﹤0.01% | 850 |
|
|
2022
Q2 | $130K | Sell |
18,653
-16,178
| -46% | -$119K | ﹤0.01% | 897 |
|
|
2022
Q1 | $288K | Buy |
34,831
+3,655
| +12% | +$25.8K | ﹤0.01% | 823 |
|
|
2021
Q4 | $211K | Sell |
31,176
-39,460
| -56% | -$259K | ﹤0.01% | 943 |
|
|
2021
Q3 | $374K | Buy |
70,636
+33,283
| +89% | +$182K | 0.01% | 683 |
|
|
2021
Q2 | $215K | Sell |
37,353
-17,931
| -32% | -$92.5K | ﹤0.01% | 847 |
|
|
2021
Q1 | $255K | Buy |
+55,284
| New | +$220K | ﹤0.01% | 723 |
|
|
2020
Q4 | – | Sell |
-19,692
| Closed | -$58K | – | 815 |
|
|
2020
Q3 | $58K | Sell |
19,692
-6,512
| -25% | -$25.5K | ﹤0.01% | 624 |
|
|
2020
Q2 | $121K | Sell |
26,204
-720
| -3% | -$3.23K | ﹤0.01% | 571 |
|
|
2020
Q1 | $104K | Sell |
26,924
-1,292
| -5% | -$5.3K | ﹤0.01% | 556 |
|
|
2019
Q4 | $106K | Sell |
28,216
-1,176
| -4% | -$5.5K | ﹤0.01% | 639 |
|
|
2019
Q3 | $156K | Sell |
29,392
-56,912
| -66% | -$303K | 0.01% | 559 |
|
|
2019
Q2 | $331K | Sell |
86,304
-40,099
| -32% | -$173K | 0.02% | 401 |
|
|
2019
Q1 | $644K | Buy |
126,403
+13,380
| +12% | +$39.3K | 0.04% | 246 |
|
|
2018
Q4 | $217K | Buy |
113,023
+12,818
| +13% | +$36.7K | 0.02% | 381 |
|
|
2018
Q3 | $378K | Buy |
100,205
+12,699
| +15% | +$39.8K | 0.04% | 294 |
|
|
2018
Q2 | $273K | Buy |
87,506
+27,766
| +46% | +$84.2K | 0.03% | 329 |
|
|
2018
Q1 | $142K | Buy |
+59,740
| New | +$199K | 0.02% | 383 |
|
Other funds holding CPRX
VCM
DM
VPM
Lido Advisors's CPRX Position: Q1 2026 in Review
Lido Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 5.8% in Q1 2026, selling an estimated $39.6K and leaving 26,841 shares worth $665K. The position accounts for ﹤0.01% of the portfolio, ranked #1153.
Lido Advisors first reported a position in CPRX in Q1 2018 and has held it in 32 quarters since. The position peaked at $763K in Q1 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Lido Advisors held 26,841 shares of Catalyst Pharmaceutical worth $665K as of Q1 2026.
- Lido Advisors sold 1,664 Catalyst Pharmaceutical shares in Q1 2026, an estimated $39.6K.
- Catalyst Pharmaceutical made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1153 holding.
- Lido Advisors first reported a position in Catalyst Pharmaceutical in Q1 2018 and has held it in 32 quarters since.
- Lido Advisors's Catalyst Pharmaceutical position peaked at $763K in Q1 2023.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.